Cargando…
Compensatory Upregulation of LPA(2) and Activation of the PI3K-Akt Pathway Prevent LPA(5)-Dependent Loss of Intestinal Epithelial Cells in Intestinal Organoids
Renewal of the intestinal epithelium is orchestrated by regenerative epithelial proliferation within crypts. Recent studies have shown that lysophosphatidic acid (LPA) can maintain intestinal epithelial renewal in vitro and conditional deletion of Lpar5 (Lpar5(iKO)) in mice ablates the intestinal ep...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324510/ https://www.ncbi.nlm.nih.gov/pubmed/35883686 http://dx.doi.org/10.3390/cells11142243 |
Sumario: | Renewal of the intestinal epithelium is orchestrated by regenerative epithelial proliferation within crypts. Recent studies have shown that lysophosphatidic acid (LPA) can maintain intestinal epithelial renewal in vitro and conditional deletion of Lpar5 (Lpar5(iKO)) in mice ablates the intestinal epithelium and increases morbidity. In contrast, constitutive Lpar5 deletion (Lpar5(cKO)) does not cause a defect in intestinal crypt regeneration. In this study, we investigated whether another LPA receptor (LPAR) compensates for constitutive loss of LPA(5) function to allow regeneration of intestinal epithelium. In Lpar5(cKO) intestinal epithelial cells (IECs), Lpar2 was upregulated and blocking LPA(2) function reduced proliferation and increased apoptosis of Lpar5(cKO) IECs. Similar to Lpar5(cKO) mice, the absence of Lpar2 (Lpar2(−/−)) resulted in upregulation of Lpar5 in IECs, indicating that LPA(2) and LPA(5) reciprocally compensate for the loss of each other. Blocking LPA(2) in Lpar5(cKO) enteroids reduced phosphorylation of Akt, indicating that LPA(2) maintains the growth of Lpar5(cKO) enteroids through activation of the PI3K-Akt pathway. The present study provides evidence that loss of an LPAR can be compensated by another LPAR. This ability to compensate needs to be considered in studies aimed to define receptor functions or test the efficacy of a LPAR-targeting drug using genetically engineered animal models. |
---|